Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment

Documenti analoghi

• Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta
  di: Brownfoot, Fiona C., et al.
  Pubblicazione: (2016)
• Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia
  di: Hannan, Natalie J., et al.
  Pubblicazione: (2018)
• Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction – implications for treating preeclampsia
  di: Kaitu’u-Lino, Tu’uhevaha J., et al.
  Pubblicazione: (2018)
• MMP-15 Is Upregulated in Preeclampsia, but Does Not Cleave Endoglin to Produce Soluble Endoglin
  di: Kaitu’u-Lino, Tu’uhevaha J., et al.
  Pubblicazione: (2012)
• Soluble fms-Like Tyrosine Kinase 1 (sFlt1), Endoglin and Placental Growth Factor (PlGF) in Preeclampsia among High Risk Pregnancies
  di: Powers, Robert W., et al.
  Pubblicazione: (2010)